Musculoskeletal Disorders
Atom Bioscience reports positive Phase IIa chronic gout therapy trial data
Atom Bioscience has reported positive data from its China Phase IIa study of ABP-671 for the treatment of chronic gout.…
Incannex begins Phase II trial of combination drug for rheumatoid arthritis
Incannex Healthcare has commenced a Phase II clinical trial of its anti-inflammatory combination drug IHL-675A in patients with rheumatoid arthritis…
Maze Therapeutics reports positive data from Pompe disease therapy trial
Maze Therapeutics has reported positive data from its Phase I clinical trial of oral glycogen synthase (GYS1) inhibitor MZE001 in…
Avidity reports data from Phase I/II myotonic dystrophy type 1 trial
Avidity Biosciences has reported positive initial analysis data from the Phase I/II MARINA clinical trial of AOC 1001 in adults…
Pipeline Moves: trial completions in glaucoma, lung, and oncology indications
This week on Pipeline Moves, we look into the completion of a Phase III trial in open-angle glaucoma. For Phase…
Peptilogics doses first subject in periprosthetic joint infection trial
Peptilogics has dosed the first subject in the Phase Ib LOGIC-1 clinical trial of investigational product PLG0206 to treat periprosthetic joint infections…
Avidity launches Phase I/II muscular dystrophy treatment trial
Avidity Biosciences has launched the Phase I/II FORTITUDE clinical trial of AOC 1020 in adult patients with facioscapulohumeral muscular dystrophy…
FDA places partial hold on Avidity’s Phase I/II myotonic dystrophy trial
The US Food and Drug Administration (FDA) has placed a partial hold on Avidity Biosciences’ Phase I/II MARINA clinical trial of AOC…
Atamyo doses first subject in Phase I/II muscular dystrophy therapy trial
Atamyo Therapeutics has dosed the first subject in a Phase I/II clinical trial of ATA-100 to treat FRKP-related limb-girdle muscular dystrophy type…
Santhera and ReveraGen dose first subject in Phase II trial of BMD drug
Santhera Pharmaceuticals and ReveraGen BioPharma have dosed the first subject in a Phase II pilot clinical trial of drug candidate…